During the 83rd Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), this time in the Pennine Acute Hospitals Trust.
In the United Kingdom, where switching patients to biosimilars has become more common as National Health Service trusts seek to benefit from cost savings, multiple reports have noted the feasibility of switching patients to biosimilar infliximab.
During the 83rd Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), this time in the Pennine Acute Hospitals Trust.
The research team, led by Anirudh Pramod Bhandare, MBBS, MD, performed a retrospective review of patients with inflammatory bowel disease who were switched from the reference product to the biosimilar, and analyzed disease demographics, the clinical course of disease, and outcomes until the time of the last follow-up.
In total, 96 patients were switched, 44 of whom had ulcerative colitis (UC) and 52 of whom had Crohn disease (CD). The mean age at diagnosis was 34.73 years. The mean duration of treatment with the reference was 49.8 months, and the mean duration of treatment with the biosimilar at the time of the review was 7.9 months.
At the time of the switch, 76 patients had normal C-reactive protein (CRP) levels, while 15 patients had elevated levels. At follow-up, 14 patients had an increase in CRP. Eighty patients remained in biochemical remission.
In 31 patients, therapeutic drug monitoring was performed. In 28 patients, infliximab was maintained in the therapeutic range, while 3 patients required dose intensification.
At the time of the last follow-up, 72 patients (34 with UC and 38 with CD) were in clinical remission, and 31 patients (13 with UC and 18 with CD) had achieved mucosal healing.
The investigators concluded that biosimilar infliximab was well tolerated and maintained efficacy in patients who switched, which indicates that switching can “fulfill the purported aims of improving access to treatment and reducing costs.”
Reference
Bhandare AP, Nigam GB, Nayeemudin S, Limdi JK. Efficacy and tolerability of a biosimilar infliximab switch—a large single-centre experience from the U.K. Presented at the 83rd Annual Scientific Meeting of the American College of Gastroenterology, October 5-10, 2018; Philadelphia, Pennsylvania. Abstract 676. https://www.nature.com/articles/s41395-018-0296-0.pdf.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.